Advertisement

Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes

  • Walter Ageno
DEBATE

Abstract

Betrixaban is a direct factor Xa inhibitor with a renal excretion of only approximately 5–7%. On June 23rd 2017, it became the first direct oral anticoagulant to receive Food and Drug Administration approval for the prevention of venous thromboembolism in acutely ill medical patients, and the first anticoagulant agent to be approved for extended-duration thromboprophylaxis after hospital discharge in this setting. Approval followed the results of the APEX trial, a phase III clinical trial comparing betrixaban (80 mg) administered for 35–42 days with enoxaparin (40 mg) administered for 10 ± 4 days. This study for the first time applied a risk assessment model, integrating clinical factors and a laboratory marker to identify high risk patients. To improve safety, a dose reduction was used for patients with creatinine clearance between 15 and 30 mL/min (betrixaban 40 mg and enoxaparin 20 mg) and for patients receiving concomitant treatment with potent P-glycoprotein inhibitors (betrixaban 40 mg). The primary prespecified analysis tested the hypothesis that the benefit of extended thromboprophylaxis with betrixaban was greatest in patients with elevated D-dimer, but the 21% relative risk reduction failed to meet the prespecified threshold for statistical significance. However, the analysis of the overall study population showed a favorable net clinical benefit with betrixaban, with a statistically significant reduction in all efficacy outcomes and no increase in major bleeding rates. An ongoing trial, MARINER, is also assessing a combined approach for risk stratification comparing extended-duration rivaroxaban with standard duration low molecular weight heparin.

Keywords

Betrixaban Enoxaparin Prophylaxis Medical patients 

Notes

Compliance with ethical standard

Conflict of interest

None.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534–544CrossRefPubMedGoogle Scholar
  2. 2.
    Stuck AK, Spirk D, Schaudt J et al (2017) Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review. Thromb Haemost 117:801–808CrossRefPubMedGoogle Scholar
  3. 3.
    Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J Thromb Haemost 8:2450–2457CrossRefPubMedGoogle Scholar
  4. 4.
    Monreal M, Kakkar AK, Caprini JA et al (2004) The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost 2:1892–1898CrossRefPubMedGoogle Scholar
  5. 5.
    Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin study group. N Engl J Med 341:793–800CrossRefPubMedGoogle Scholar
  6. 6.
    Leizorovicz A, Cohen AT, Turpie AGG et al (2004) Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879CrossRefPubMedGoogle Scholar
  7. 7.
    Cohen AT, Davidson BL, Gallus AS et al (2006) Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325–329CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hull RD, Merali T, Mills A et al (2013) Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clin Appl Thromb Haemost 19:357–362CrossRefGoogle Scholar
  9. 9.
    Mahan CE, Fisher MD, Mills RM et al (2013) Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patients population. Thromb Res 132:520–526CrossRefPubMedGoogle Scholar
  10. 10.
    Hull RD, Schellong SM, Tapson VF et al (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153:8–18CrossRefPubMedGoogle Scholar
  11. 11.
    Cohen AT, Spiro TE, Büller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523CrossRefPubMedGoogle Scholar
  12. 12.
    Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2217CrossRefPubMedGoogle Scholar
  13. 13.
    Imberti D, Benedetti R, Ageno W (2013) Prevention of venous thromboembolism in acutely ill medical patients after the results of recent trials with the new oral anticoagulants. Intern Emerg Med 8:667–672CrossRefPubMedGoogle Scholar
  14. 14.
    Kahn S, Lim W, Dunn AS et al (2012) Prevention of VTE in non surgical patients. Chest 141(Suppl 2):e195S–e226SCrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yusen RD, Hull RD, Schellong SM et al (2013) Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Thromb Haemost 110:1152–1163CrossRefPubMedGoogle Scholar
  16. 16.
    Cohen AT, Spiro TE, Spyropoulos AC et al (2014) D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 12:479–487CrossRefPubMedGoogle Scholar
  17. 17.
    Decousus H, Tapson VF, Bergmann JF et al (2011) Factors at admission associated with bleeding risk in medical patients. Findings from the IMPROVE investigators. Chest 139:69–79CrossRefPubMedGoogle Scholar
  18. 18.
    Ageno W, Riva N, Noris P et al (2012) Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost 10:2291–2297CrossRefPubMedGoogle Scholar
  19. 19.
    Gibson CM, Chi G, Halaby R et al (2017) Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy. Circulation 135:648–655CrossRefPubMedGoogle Scholar
  20. 20.
    Gibson CM, Halaby R, Korjian S et al (2017) The safety and efficacy of full-versus reduced-dose betrixaban in the acute medically Ill VTE prevention with extended-duration betrixaban (APEX) trial. Am Heart J 185:93–100CrossRefPubMedGoogle Scholar
  21. 21.
    Raskob GE, Spyropoulos AC, Zrubek J et al (2016) The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 115:1240–1248CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2017

Authors and Affiliations

  1. 1.Department of Medicine and SurgeryUniversity of InsubriaVareseItaly
  2. 2.Short Medical Stay Unit and Thrombosis CenterOspedale di Circolo Fondazione MacchiVareseItaly

Personalised recommendations